Important: This article is for educational purposes only and is not medical advice. Schizophrenia is a serious psychiatric condition that requires care from a board-certified psychiatrist. CBD is not approved by the FDA to treat schizophrenia. Never stop, switch, or substitute prescribed antipsychotic medication without psychiatric supervision — doing so can be dangerous.
A small number of clinical studies have examined cannabidiol (CBD) in patients with schizophrenia, and that research has occasionally been miscommunicated in popular media as a “natural” alternative to antipsychotics. It is not. This page explains what those studies actually examined, why their findings cannot be extrapolated to consumer CBD products, and why any conversation about CBD and schizophrenia belongs with a treating psychiatrist.
The short version
- CBD is not a treatment for schizophrenia. No CBD product, consumer or pharmaceutical, is FDA-approved for any schizophrenia spectrum disorder.
- A small number of academic clinical trials have explored whether CBD added to standard antipsychotic care might affect specific symptom measures. These were not consumer products and not large enough to change practice guidelines.
- Schizophrenia care typically involves prescribed antipsychotic medication, psychotherapy (including CBT for psychosis), and psychosocial support. Stopping prescribed medication is associated with relapse and rehospitalization risk.
What schizophrenia is, briefly
Schizophrenia is a psychiatric condition that affects perception, thought, mood, and behavior. It commonly involves positive symptoms (hallucinations, delusions, disorganized thinking), negative symptoms (reduced motivation, blunted affect), and cognitive symptoms (difficulty with attention and working memory). It typically emerges in late adolescence or early adulthood and is managed long-term.
Standard care includes antipsychotic medications (older “typical” agents such as haloperidol and newer “atypical” agents such as risperidone, olanzapine, aripiprazole, and clozapine for treatment-resistant cases), structured therapy, and supports for housing, employment, and family education. The condition is highly individual, and treatment plans are built by treating psychiatrists.
What CBD-and-schizophrenia research has actually examined
The most-cited clinical work is McGuire et al. (2018), published in the American Journal of Psychiatry. Key features of that trial worth knowing:
- It was a randomized, placebo-controlled trial that added 1,000 mg/day of pharmaceutical-grade CBD to existing antipsychotic treatment in 88 patients.
- It was an add-on trial, not a replacement trial. All patients continued taking their prescribed antipsychotics.
- The CBD arm showed modest improvements on certain symptom scales relative to placebo, but the study was small and the results were not large enough to change clinical practice.
- The dose was pharmaceutical-grade CBD at 1,000 mg/day — orders of magnitude higher than the doses in consumer CBD products and not recommended for self-administration.
Other published work has been mostly preclinical (animal models examining cannabinoid receptor signaling) or earlier human pharmacology studies. None of it supports marketing consumer CBD as a treatment for schizophrenia.
Why this is not “CBD as antipsychotic”
A few points are essential:
- It was an add-on, not a substitution. No reputable researcher has ever tested whether patients with schizophrenia can safely substitute CBD for prescribed antipsychotics. Doing so risks psychotic relapse.
- The doses studied are not the doses in consumer products. A typical wellness CBD product is dosed in tens of milligrams. The McGuire trial dosed 1,000 mg/day. The pharmacology is not equivalent.
- Drug interactions are clinically meaningful here. Many antipsychotics are metabolized through CYP enzymes that CBD also affects. High-dose CBD added to an antipsychotic regimen is the kind of intervention that requires medical supervision and lab monitoring, not self-experimentation.
Cannabis use and psychotic disorders — a separate, important point
It is worth being clear about a related research finding: heavy cannabis use, especially of high-THC products in adolescents, is associated with increased risk of developing psychotic disorders in vulnerable individuals. This is an established public-health concern documented in epidemiological studies. CBD is not THC, but the broader cannabis context is important for anyone with a personal or family history of psychotic illness. Conversations with a psychiatrist about any cannabis-derived product are appropriate.
What the FDA has said
The FDA has not approved any CBD product for schizophrenia or any related condition. The agency has issued warning letters to companies that have marketed CBD with mental-health treatment claims, citing that such claims make those products unapproved new drugs under federal law.
This is why reputable mental-health publications and CBD brands describe the research carefully and do not market consumer CBD as a psychiatric treatment.
Talking to your psychiatrist
If you or someone you support lives with a psychotic disorder and is curious about CBD, a frank conversation with the treating psychiatrist is the right path. Useful questions:
- Are any of my current medications metabolized through pathways CBD also uses?
- Is there any specific reason I should not use a consumer CBD product?
- If I do try a CBD product, what should you know about it, and what should I report back about?
- Are there any clinical research opportunities relevant to my situation?
What we offer at New Phase Blends
We make third-party-tested CBD products designed for general wellness use. They are not formulated, tested, or marketed as treatments for schizophrenia or any psychiatric condition. If you have a psychiatric diagnosis, please continue to follow the plan your treating psychiatrist has built for you, and disclose any supplement use during clinical visits.
Frequently asked questions
Can CBD be used as an antipsychotic? No. The clinical research that exists is small, used pharmaceutical-grade CBD at doses far above consumer products, and was an add-on to existing antipsychotic treatment — not a substitute.
Has CBD been FDA-approved for schizophrenia? No.
Is it safe to stop my antipsychotic and use CBD instead? No. Stopping prescribed antipsychotic medication is associated with relapse and hospitalization risk and should never be done without psychiatric supervision.
Can CBD interact with antipsychotic medications? It can. CBD shares liver-enzyme pathways with many psychiatric medications. Any combination should be reviewed by a treating clinician.
Disclaimer: The statements made on this page have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease, including schizophrenia or any psychiatric condition. The information here is for educational purposes only. Mental-health conditions are serious; please continue to follow the plan provided by your treating clinician.
